กำลังโหลด
NASDAQHealthcareBiotechnology
ข้อมูลล่าสุด
US$0.87
−US$0.0107 · -1.21%
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
ราคาปิดก่อนหน้า
US$0.87
−US$0.0107 · -1.21%
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
ช่วงราคารายวัน
ปัจจุบัน US$0.87
ช่วง 52 สัปดาห์
ปัจจุบัน US$0.87
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
คะแนน GoAI
ถือ
มูลค่า
27
ราคาค่อนข้างแพง
ความเชื่อมั่น
68
เชิงบวก
ความเสี่ยง
58
ความเสี่ยงค่อนข้างสูง
โมเมนตัม
67
กำลังแข็งแกร่งขึ้น
งานวิจัย GoAI ฉบับเต็ม
ดูข้อมูลสนับสนุน ปัจจัยหนุน และความเสี่ยงในเชิงลึก
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
ช่วงราคารายวัน
ปัจจุบัน US$0.87
ช่วง 52 สัปดาห์
ปัจจุบัน US$0.87
ผลประกอบการล่าสุดที่ประกาศ
ผลประกอบการล่าสุดที่ประกาศ
กองทุนซื้อขายแลกเปลี่ยนที่รายงานความเสี่ยงต่อหุ้นนี้
iShares Russell 2000 ETFIWM345.42K0.00%78.74B USD0.19%US$278.94+0.49%
Vanguard Russell 2000 ETFVTWO193.51K0.00%18B USD0.06%US$112.66+0.50%
iShares Russell 2000 Growth ETFIWO99.97K0.00%13.92B USD0.24%US$356.78+0.94%
iShares Micro-Cap ETFIWC41.81K0.00%1.32B USD0.60%US$183+0.11%
Vanguard Russell 2000 Growth ETFVTWG21.67K0.00%1.7B USD0.06%US$260.49+0.91%
Vanguard Russell 2000 Value ETFVTWV14.55K0.00%1.4B USD0.06%US$185.81-0.13%
Global X - Russell 2000 ETFRSSL6.27K—1.42B USD0.08%US$109.09+0.21%
ProShares Russell 2000 High Income ETFITWO760.380.00%184.98M USD0.55%US$43.06+0.96%iShares Russell 2000 ETFIWMVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGVanguard Russell 2000 Value ETFVTWVGlobal X - Russell 2000 ETFRSSLProShares Russell 2000 High Income ETFITWOเนื้อหาที่สร้างโดย AI และข้อมูลตลาดที่ล่าช้ามีไว้เพื่อให้ข้อมูลและการศึกษาเท่านั้น ไม่ใช่คำแนะนำการลงทุน
